- Clinical and translational research in lymphoma, with a focus on stem cell transplantation and development of novel therapies, as well as late effects of treatment
- Applied molecular oncology
R Michael Crump
Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
Lancet Oncol. 2017 Dec 21;:
Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma.
Clin Cancer Res. 2016 Oct 01;22(19):4807-4816
Clin Cancer Res. 2016 May 01;22(9):2290-300
Effectiveness and tolerability of first-line autologous stem cell transplant and maintenance rituximab for mantle cell lymphoma.
Bone Marrow Transplant. 2017 Dec 21;:
A bio-clinical prognostic model using MYC and BCL2 predicts outcome in relapsed/refractory diffuse large B-cell lymphoma.
Haematologica. 2017 Nov 02;:
Am J Kidney Dis. 2017 Jun 22;:
Bleomycin pulmonary toxicity does not adversely affect the outcome of patients with Hodgkin lymphoma.
Leuk Lymphoma. 2017 May 15;:1-8
Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study().
Leuk Lymphoma. 2017 May 15;:1-9
A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma.
Br J Haematol. 2017 Apr 25;:
Lancet Oncol. 2017 Feb 22;:
Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre